Miramar resort redevelopment expected to be finished in 2018
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
FDA gives big win to Amgen in biosimilars race
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Santa Barbara 100 bicycle ride aims to be world-class event
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Dubroff: CLU professor scales the summit of Central Coast economics
A rock climbing expert with an innate curiosity about markets, Matthew Fienup found his calling in his mid-30s when he won admission to a doctoral program at UC Santa Barbara’s Bren School of Environmental Management. Now 41 and a professor in California Lutheran University’s Center for Economic Research & Forecasting, he’ll get a view from Read More →
Amgen paying Arrowhead for traits to develop cardiovascular drugs
Amgen will license two traits from a Pasadena pharmaceutical company to develop cardiovascular drugs under a partnership announced Sept. 29. Under the agreement, Thousand Oaks-based Amgen will pay Arrowhead Pharmaceuticals $35 million up front, $21.5 million in the form of an equity investment by Amgen in Arrowhead common stock, and up to $617 million in Read More →
Amgen announces positive results for migraine drug
Thousand Oaks-based biotech giant Amgen announced positive data from a phase 3 study of a new migraine drug co-developed with competitor Novartis. Amgen said in a news release that, after 12 weeks, Erenumab showed a significant reduction in monthly migraine days in patients with episodic migraines treated with Erenumab compared with a placebo. In the Read More →
CalAmp misses analyst estimates for second quarter
CalAmp fell short of revenue and earnings per share estimates for the second quarter, the company reported Sept. 29. Net income was $521,000, which was down from $3.4 million in the second quarter of 2015. CalAmp posted revenues of $90.5 million, up from revenues of $69.8 million during the same quarter in 2015 but just Read More →
